Ulocuplumab

N/A

Report date: 2024/05/04 20:00:04

Base Information

Drug NameUlocuplumab
Drug Alias Name乌洛鲁单抗ulocuplumabum乌洛克人单抗BMS-936564MDX-1338
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsSolid tumoursWaldenstrom MacroglobulinemiaMultiple Myeloma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsSolid tumoursWaldenstrom MacroglobulinemiaMultiple Myeloma +[8] 

Other Information

ATC CodeN/A
Related LinksWikipedia